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Abstract
Background: Crohn’s disease (CD) is a chronic trans-
mural inflammation of the gastrointestinal tract of unk-
nown cause. Malnutrition associated with active CD has 
been reduced although obesity has increased. Dietary 
strategies such as those with high-protein have been pro-
posed to reduce body fat. This study compares the effects 
of two supplements on the nutritional status of CD pa-
tients.
Materials and Methods: 68 CD patients were rando-
mized in two groups: whey protein group (WP) and soy 
protein group (SP). Using bioimpedance analysis, an-
thropometry and albumin and pre-albumin dosages the 
nutritional status was measured before starting the in-
tervention and after 8 and 16 weeks. The disease activity 
was determined by Crohn’s Disease Activity Index and 
serum C-reactive protein dosage and dietary intake by 
24h dietary recalls.
Results: Forty-one patients concluded the study and 
both supplements changed body composition similarly. 
Triceps skin fold thickness (p< 0.001) and body fat per-
centage (p=0.001) decreased, whereas mid-arm muscle 
circumference (p=0.004), corrected arm muscle area 
(p=0.005) and body lean percentage (p=0.001) increased.
Conclusions: For Crohn’s disease patients undergoing 
anti TNF-alpha and azatioprine therapies, supplementa-
tion with whey and soy proteins changes body composi-
tion through reduction of body fat and thus contributes 
to control inflammation.
(Nutr Hosp. 2015;31:1603-1610)
DOI:10.3305/nh.2015.31.4.8362
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SUPLEMENTOS DE PROTEÍNA DE SUERO Y 
SOYA CAMBIA LA COMPOSICIÓN CORPORAL 
EN LOS PACIENTES CON ENFERMEDAD DE 
CROHN SOMETIDOS CON AZATIOPRINA Y 
ANTI-TNF-ALFA TERAPIAS
Resumen
Introducción: La enfermedad de Crohn (EC) es un tras-
torno inflamatorio crónico transmural del tracto gastroin-
testinal de carácter desconocida. La desnutrición asociada 
con EC activa se ha reducido a pesar de la obesidad que ha 
aumentado. Se han propuesto estrategias dietéticas, como 
aquellos con alto contenido de proteínas para reducir la gra-
sa corporal. Este estudio compara los efectos de dos suple-
mentos sobre el estado nutricional de los pacientes con EC.
Materiales y Métodos: Fueron randomizados en dos 
grupos 68 pacientes con EC: el grupo de proteína de sue-
ro y el grupo de proteína de soya. Se utilizo el análisis 
de bioimpedancia eléctrica, la antropometría y dosifica-
ciones de albúmina y prealbúmina del estado nutricional 
midiéndose antes de comenzar la intervención y después 
de 8 y 16 semanas. La actividad de la enfermedad se de-
terminó por Índice de Actividad de Enfermedad de Cro-
hn (CDAI), dosificación en suero de la proteína C reacti-
va y la ingesta dietética por recordatorio de 24h.
Resultados: Cuarenta y un pacientes concluyeron el 
estudio y ambos suplementos cambiaron la composi-
ción corporal de manera similar. El espesor del pliegue 
cutáneo del tríceps (p <0,001) y el porcentaje de grasa 
corporal (p = 0,001) se redujeron, mientras que la circun-
ferencia muscular braquial (p = 0,004), el área muscular 
del brazo corregida (p = 0,005) y el porcentaje corporal 
magra (p = 0,001) han aumentado.
Conclusiones: En los pacientes con enfermedad de 
Crohn sometidos con anti-TNF-alfa y terapias azatiopri-
na, la suplementación con proteínas de suero de leche y 
de soya cambia la composición corporal a través de la 
reducción de la grasa corporal y por lo tanto contribuye 
para controlar la inflamación.
(Nutr Hosp. 2015;31:1603-1610)
DOI:10.3305/nh.2015.31.4.8362
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Background
Crohn’s disease (CD) is a chronic inflammatory di-
sease of the gastrointestinal tract. Complications such 
as obstruction, fistulas and abscesses can appear du-
ring the course of the disease1,2.
The CD Activity Index (CDAI) and the Har-
vey-Bradshaw Index (HBI) have been recommended 
to assess CD activity. The CDAI has been considered 
the gold standard for clinical trials3. However, this in-
dex does not take into account objective measures of 
inflammation such as C-reactive protein (CRP) and en-
doscopic lesions. A recent study showed that the CDAI 
is not a reliable measure to predict endoscopic and/
or CRP remission among patients under azathioprine 
and/or infliximab4. This result indicates that the index 
will probably be updated or changed.
CD is traditionally associated with weight loss, but 
with the development of new therapies and early inter-
ventions this may be changing. Nowadays, obesity has 
also occurred5,6. The mechanisms underlying the puta-
tive effects of overweight and obesity on CD are unk-
nown. It has been demonstrated that a production of 
proinflammatory cytokines from adipose tissue such 
as tumor necrosis factor alpha (TNF-alpha), interleu-
kin six (IL-6) and adipokines are elevated in obesity7. 
This inflammatory state may have detrimental effects 
on CD, creating a favorable environment for gut in-
flammation and progression of disease8,9,10.
Intake of protein has been shown to influence satie-
ty, thermogenesis and body composition. Soy protein 
(SP) reduced body fat in obese rats and whey protein 
(WP) in obese humans has the same effect11-14. The 
study with WP intake in CD patients was the open-la-
bel which showed reduction in body fat15. WP intake 
has stimulated glutathione synthesis in HIV infected 
children16, reduced IL-6 and increased glutathione in 
patients with ischemic stroke17.
Based on the results of our previous open-label 
study15, the aim of the present study was to compare 
the effect of whey Protein (WP) and soy Protein (SP) 
supplements on body composition and disease activity 
in CD patients.
Methods
Trial design
This was a randomized, parallel-arm, 16-week 
study, conducted in line with CONSORT recommen-
dations. Patients with Crohn’s Disease were recruited 
from February to October 2012 in the Inflammatory 
Bowel Disease outpatient clinic at the University Me-
dical School of Campinas, SP - Brazil. The sample size 
was based on the results of our previous open-label15 
and calculated to determine a 15% change in body 
fat percentage (P=0.05) with 80% power among each 
group comparison.
Patients
The trial included CD patients treated with aza-
thioprine or anti-tumor necrosis factor-alpha (an-
ti-TNF-alpha) or azathioprine and anti-TNF-alpha and 
excluded smokers and those who were using other me-
dication or nutritional supplements.
Trial protocol
The protocol of the study was approved by the 
Ethics Committee of the University of Campinas 
(CAAE: 10990146000-11) and registered on Clinical-
Trials.gov. Identifier: NCT01957423.
A random number sequence, generated by Microsoft 
Office Excel 12.0 (Office 2007), was used to designa-
te the treatment assignment. We used blocks of size 2 
at random to create the allocation sequence. Patients 
were randomized 1:1 for each group: one supplemen-
ted with a concentrate of whey protein (WP) donated 
by Hilmar Cheese and the other, with an isolate soy 
protein (SP) from Probiótica (compositions specified 
in table I). Randomization and allocation were con-
ducted by the “blinded” researcher.
WP and SP were provided as identical sachets with 
15g and 12g of supplement, respectively. Sachets were 
packed in bags with a code for each supplement, A or 
B. Both patients and researchers were unaware of the 
treatment assignation. Patients were advised to consu-
me two sachets per day (amounting to 22.4g of pro-
tein) mixed with food or a cold beverage immediately 
after opening the sachet, for 16 weeks. All patients 
remained on an unrestricted diet and did not receive 
nutritional advice.
Compliance was checked every two weeks by pho-
ne and also by counting the number of packets not con-
sumed.
Follow-up Assessment
The body composition in the three evaluations was 
measured at the same period of the day, using bioim-
pedance analysis. Whole-body resistance and reac-
tance were measured using a tetrapolar bioelectrical 
impedance analyzer in accordance with the manufac-
turer’s guidelines (BIODYNAMICS, Model 310e). 
This analyzer provides data on lean mass and fat mass. 
Nutritional status was additionally assessed using an-
thropometric parameters. Body weight was measured 
by a medical decimal scale to an accuracy of 0.01 kg. 
Body height was measured to the nearest millimeter 
using a stadiometer. Body mass index (BMI) was cal-
culated from weight and height (kilograms per meter 
squared) and classified according to the World Heal-
th Organization. Mid-arm circumference (MAC) and 
triceps skin fold thickness (TSF) were obtained using 
the tape measure and Lange skin fold caliper. Mid-arm 
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muscle circumference (MAMC) and corrected arm 
muscle area (CAMA) were calculated from MAC and 
TSF. All measurements were obtained by the same ob-
server according to the National Health and Nutrition 
Examination Survey and results were compared with 
reference values provided by Frisancho AR18.
For the evaluation of disease activity, the Crohn’s 
Disease Activity Index – CDAI19 was used. Blood sam-
ples were drawn to determine biochemical parameters, 
serum albumin, pre-albumin, C-reactive protein (CRP) 
and hemogram, measured by routine methods in use at 
the University of Campinas Medical School.
The dietary intake was assessed by 24h recalls, be-
fore the intervention and after 8 and 16 weeks. Food 
portion sizes were estimated by the patients with the 
help of photos shown to them. Macronutrients and mi-
cronutrients were calculated with the help of software 
for nutrient evaluation (Dietpro 5.i). Tables of the Die-
tary Reference Intakes – DRIs were used to evaluate 
the adequacy of the nutrient intake.
Statistics
Statistical analyses were performed using SPSS 
16.0 software package. The correlations between the 
biochemical and clinical measurements were calcula-
ted employing a bivariate correlation with a non-pa-
rametric distribution (Spearman’s rho). Comparison 
of categorical data between the groups was perfor-
med using the χ² method or Fisher exact test. Com-
parison of continuous data between the groups was 
performed using the Student t test for the normal data 
or Mann-Whitney test for the non-normal data. One-
Way Repeated ANOVA was used for comparison of 
continuous data between the different times in which 
the patients were evaluated. For non-normal data the 
Friedman test was used. A level of 5% significance 
was established.
Results
Patient cohort
The flowchart of the randomized trial is shown in 
figure 1. Forty-one patients (19 of WP, 22 of SP) com-
pleted the 16-week supplementation period. Clinical, 
nutritional and demographic data at baseline of these 
patients are in table II. There were no statistical diffe-
rences between the groups, table III.
Biochemical and clinical outcomes
There was no significant difference between groups 
(before, during and after the nutritional supplementa-
tion) to albumin, pre-albumin, CRP and CDAI. There 
was a significant positive correlation between CDAI 
and CRP (r = 0.36, P = 0.019) of the two groups. Fur-
thermore, CDAI and CRP were negatively correla-
ted with albumin (r = -0.39, P = 0.012; r = -0.54, P < 
0.001) and pre-albumin (r = -0.31, P = 0.046; r = -0.65, 
P < 0.001).
Nutritional outcome
BMI was similar for both groups. At the first eva-
luation, 19.5% of patients were overweight and 9.8% 
obese and only one was malnourished.
The two supplements changed body composition. 
Body fat percentage (Fig. 2A) and TSF (Fig. 2C) 
decreased, whereas body lean percentage (Fig. 2B), 
MAMC (Fig. 2D) and CAMA (Fig. 2E) increased.
Table I
Chemical composition of the whey protein (WP) 
and soy protein (SP) treatment supplements1
WP SP
g/100g
Protein 73.5 90.0
Moisture 6.3 6.0
Total fat 13.9 0.5
Total carbohydrate 6.6 1.0
Alanine 5.0 3.9
Arginine 3.3 7.3
Cystine 2.3 1.3
Phenylalanine 3.5 5.1
Glycine 2.1 3.9
Histidine 1.9 2.2
Isoleucine 5.8 4.2
Leucine 10.3 7.6
Lysine 8.6 5.9
Methionine 3.1 1.2
Proline 5.9 5.5
Serline 5.5 5.0
Tyrosine 3.2 3.5
Threonine 6.3 3.4
Tryptophan 1.1 1.5
Valine 5.3 4.6
Asparticacid 10.9 11.2
Glutamicacid 16.9 20.5
Isoflavone 0.0 0.2
¹Chemical compositions were determined by Institute of Food 
Technology, São Paulo, Brazil and Department of Food and 
Nutrition, Faculty of Food Engineering, State University of 
Campinas, São Paulo, Brazil.
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Dietary Intake
Intake of micronutrients did not change during the 
study. Considering the two groups, the daily energy of the 
first dietary recall was 1962.8 ± 646.0 kcal/day and the 
percentage of carbohydrate, protein and lipids relative to 
total energy were, respectively: 49.1± 8.4%; 18.3 ± 5.1%; 
32.6 ± 7.6%, which were in accordance with the DRIs.
We observed some deficiencies of the micronutrient 
intake in comparison with the DRIs. Figure 3 shows 
the proportion of patients whose nutrient intake was 
below the recommendation in the first evaluation.
Fig. 1.—Flow chart of the rando-
mization of the two groups.
Fig. 2.—Effect of whey protein and soy protein. A-body fat percentage (%BF); B-body lean percentage (%BL); C-triceps skin fold (TSF); 
D-mid-arm muscle circumference (MAMC); E-corrected arm muscle area (CAMA). There were significant differences within groups 
(ANOVA).
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Patients who withdrew from the study
Twenty-seven patients did not complete the study 
(10 men and 17 women). Clinical, nutritional and de-
mographic data at baseline of these patients are in table 
II. Of these patients, 51.9% were under anti-TNF-al-
pha therapy, 33.3% were under azathioprine therapy 
and the remainder used both drugs. Concerning BMI, 
51.9% were eutrophic, 33.3% overweight, 7.4% obe-
se and 7.4% undernourished. Only one patient had a 
CDAI greater than 150 (166), and BMI of 36.5 kg / 
m². They had a higher mean TSF (p = 0.02) than the 
group that completed the study (Table II). After 16 
weeks the excluded group did not show changes in 
CRP (0.6 ± 0.9mg/dL, p=0.5) or CDAI (64.21 ± 68.8, 
p=0.9) mean. The reasons why these patients left the 
study were: 11 did not like the taste, 8 had diarrhea and 
nausea, 6 did not follow the intake schedule and 2 had 
skin reaction.
Discussion
The results of this randomized study demonstrated 
that nutritional supplementation with WP or SP in pa-
tients with CD changed body composition but had no 
Table II
Characteristics of the patients at baseline
Characteristics
Patients who completed
the study (n=41)
Patients who completed
the study (n=27)
p Value1
Mean (SD) age, years 40.2 (10.8) 38.3 (12.8) 0.51
Male, n (%) 29 (70.7) 10 (37.0) 0.06
Mean (SDD) duration of CD2 years 10.3 (6.8) 11.4 (7.1) 0.53
Mean (SD) CDAI3 73.8 (69.7) 56.0 (43.1) 0.11
Resection4, n (%) 21 (51.2) 18 (66.7) 0.21
Disease site
Colon/rectum/anal canal, n (%) 14 (34.1) 6 (22.2)
SB5, n (%) 15 (36.6) 13 (48.1) 0.39
Colon/rectum/anal canal, + SB5, n (%) 12 (29.3) 8 (29.6)
Medication
Azathioprine, n (%) 22 (53.7) 9 (33.3)
Anti-TNF-a, n (%) 14 (34.1) 14 (51.9) 0.25
Azathioprine + Anti-TNF-a, n (%) 5 (12.2) 4 (14.8)
Laboratory parameters
Mean (SD) CRP6, mg/dL 0.8 (1.0) 0.6 (0.9) 0.30
Mean (SD) Albumin, g/dL 4.3 (0.6) 4.4 (0.4) 0.66
Mean (SD) Pre-albumin, mg/dL 30.3 (9.0) 28.8 (10.1) 0.52
Mean (SD) Homoglobin, g/dL 13.2 (1.8) 13.5 (1.5) 0.50
Mean (SD) Hematocrit, % 39.3 (6.1) 41.1 (4.0) 0.18
Nutritional parameters
Mean (SD) BMI7, kg/m2 24.1 (3.5) 24.1 (4.9) 0.98
Mean (SD) MAC8, cm 29.3 (3.3) 29.7 (3.8) 0.65
Mean (SD) TSF9, mm 18.4 (6.5) 23.2 (10.0) 0.02*
Mean (SD) MAMC10, cm 23.5 (3.7) 22.4 (3.2) 0.19
Mean (SD) CAMA11, cm2 36.4 (13.9) 33.1 (10.0) 0.29
Mean (SD) %BF12 24.7 (6.8) 28.0 (8.5) 0.08
¹p Values calculated by the Student T test for continuous data and X² test or Fisher exact test for categorical data. 2CD, Crohn’s disease; 3CDAI, 
Crohn’s Disease Activity Index; 4number of patients underwent bowel resection; 5SB, small bowel; 6CRP, C- reactive protein; 7BMI, Body Mass 
Index; 8MAC, Mid-arm circumference; 9TSF, triceps skin fold; 10MAMC, mid-arm muscle circumference; 11CAMA, corrected arm muscle area; 
12%BF, body fat percentage.
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Fig. 3.—Proportion of CD 
patients with nutrient intakes 
below DRIs.
Table III
Comparsion of WP and SP groups that completed the study, before intervention
Characteristics WP (n=19) SP (n=22) p Value1
Mean (SD) age, years 40.8 (12,4) 39.6 (9.4) 0.74
Male, n (%) 15 (78.9) 14 (63.6) 0.28
Mean (SDD) duration of CD2 years 9.3 (6.2) 11.1 (7.2) 0.40
Mean (SD) CDAI3 86.4 (73.6) 62.9 (65.8) 0.07
Mean (SD) CRP4, mg/dL 0.75 (0.8) 0.76 (1.2) 0.69
Resection5, n (%) 9 (47.4) 12 (54.5) 0.65
Disease site
Colon/rectum/anal canal, n (%) 9 (47.4) 5 (22.7)
SB6, n (%) 5 (26.3) 10 (45.5) 0.23
Colon/rectum/anal canal + SB6, n (%) 5 (26.3) 7 (31.8)
Medication
Azathioprine, n (%) 11 (57.9) 11 (50)
Anti-TNF-a, n (%) 6 (31.6) 8 (36.4) 0.88
Azathioprine + Anti-TNF-a, n (%) 2 (10.5) 3 (13.6)
¹p Values calculated by the Student t test for continuous data and X² test or Fisher exact test for categorical data. 2CD, Crohn’s disease; 3CDAI, 
Crohn’s Disease Activity Index; 4CRP, C-reactive protein, 5number of patients underwent bowel resection; 6SB, small bowel
effect on the disease activity. Several studies have eva-
luated the efficacy of enteral formulations to control the 
disease activity in CD patients20,21. In our study, most 
patients were in remission and the CDAI remained un-
changed throughout the study. We observed a weak but 
significant correlation of CRP with CDAI. Other au-
thors demonstrated an association of CRP with clinical 
activity as well as endoscopic and histologic inflam-
mation22,23. Therefore, both parameters can be used in 
clinical practice to assess the activity of Crohn’s disease.
In 2008 and 2009 data were collected from 188,000 
Brazilian people of which 50% of men and 48% of wo-
men were overweight, and 12.5% of men and 16.9% of 
women were obese24. We found 19.5% overweight and 
9.8% obese in Brazilian CD patients who tend to have the 
same lifestyle and dietary habits of the general population.
Recent research has shown an increasing prevalence 
of overweight and obesity in IBD patients5,6. Steed et 
al.6 observed 18% obese and 38% overweight in 489 
patients. Obesity and CD were associated with deve-
lopment of mesenteric fat, which produces proinflam-
matory adipokines25. The excess of these adipokines 
in CD patients with obesity may have adverse effects 
during the course of the disease9.
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Our analysis of the food consumed revealed that 
the energy and macronutrient intakes were adequate, 
but many patients had inadequate consumption of fi-
ber, calcium, potassium and vitamins A, C and D. This 
has also been observed in other studies26,27. The reason 
is that many of these patients have lactose intoleran-
ce and avoid the consumption of milk and other dairy 
products. Furthermore, diets that exclude vegetables 
and fruit are often recommended to improve gastroin-
testinal symptoms in patients with active disease and 
the majority of patients continue with this diet even 
after remission26,28. Oral supplements of calcium and 
vitamin D are often required due to the risk of bone 
disease.28 Diet counseling is important and has been 
effective in the repairing of nutrient deficiencies29.
WP mixture supplementation for 12 weeks in obese 
subjects without CD led to higher reductions of body 
fat than the control group who consumed glucose12. 
Baer et al.13 compared the supplementation of obese 
individuals with WP, SP and carbohydrates. At the end 
of the study the WP group had less body fat than the 
carbohydrate and SP groups. Our study did not show 
differences in the body composition between the WP 
and SP groups. However, the two protein sources pro-
duced the same effects in body composition after 16 
weeks of supplementation, a reduction in body fat and 
an increase in lean mass.
Although the absence of a placebo group leads to 
limitations in the study, no placebo was found with 
similar organoleptic characteristics of supplements. 
Another drawback was that there were 17 drop-out pa-
tients although clinical and laboratory differences be-
tween them and those who completed the study were 
not detected. Moreover, even after leaving the study, 
the patients did not change their clinical status. Pre-
viously, the acceptability of this WP supplement was 
evaluated30, and it was concluded that adherence to 
supplementation could be increased with an improve-
ment in its organoleptic characteristics.
Conclusion
For Crohn’s disease patients, supplementation with 
whey and soy proteins as an additional therapeutical 
intervention changes body composition through reduc-
tion of body fat and thus contributes to control inflam-
mation.
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